Literature DB >> 7793885

Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis.

P S Skinner1, S K Furney, D A Kleinert, I M Orme.   

Abstract

In this study the compounds levofloxacin and sparfloxacin, as well as three experimental compounds (AMQ2, AMQ4, and AMQ5), were compared with isoniazid and rifabutin in terms of their capacity to inhibit the intracellular growth of the drug-susceptible Mycobacterium tuberculosis strain Erdman and the isoniazid-resistant katG gene-negative strain 24 within monolayers of mouse bone marrow-derived macrophages. Both levofloxacin and sparfloxacin, as well as compound AMQ4, had substantial activity in this physiologically relevant model, further confirming the potential usefulness of this class of compounds in the therapy of tuberculosis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7793885      PMCID： PMC162617          DOI： 10.1128/AAC.39.3.750

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Structure-activity relationships of the fluoroquinolones.

Authors:  D T Chu; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

Review 2.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  Intraphagocytic penetration of antibiotics.

Authors:  P Van der Auwera; T Matsumoto; M Husson
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

4.  Pharmacokinetics of a novel quinolone, AT-4140, in animals.

Authors:  S Nakamura; N Kurobe; T Ohue; M Hashimoto; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

Review 5.  Tissue penetration of the new quinolones in humans.

Authors:  D N Gerding; J A Hitt
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

6.  Intracellular bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis H37Rv multiplying in the J-774 macrophage cell line.

Authors:  N Rastogi; M C Blom-Potar
Journal:  Zentralbl Bakteriol       Date:  1990-06

7.  Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.

Authors:  L S Young; O G Berlin; C B Inderlied
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

8.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  The pharmacokinetics and tissue penetration of ofloxacin.

Authors:  M R Lockley; R Wise; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

Review 10.  Present status of chemotherapy for tuberculosis.

Authors:  J H Grosset
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr
View more
  10 in total

1.  Search for new drugs for treatment of tuberculosis.

Authors:  I Orme
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Fluoroquinolone transport by human monocytes: characterization and comparison to other cells of myeloid lineage.

Authors:  S J Bounds; R Nakkula; J D Walters
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Drug effects on intracellular mycobacteria determined by mass spectrometric analysis of the Na(+)-to-K+ ratios of individual bacterial organisms.

Authors:  M Wiese; U Seydel
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 4.  Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action.

Authors:  Saifur R Khan; Yousef Manialawy; Arno G Siraki
Journal:  Br J Pharmacol       Date:  2019-11-12       Impact factor: 8.739

5.  Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.

Authors:  N Rastogi; K S Goh; A Bryskier; A Devallois
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis.

Authors:  N Rastogi; K S Goh; A Bryskier; A Devallois
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

7.  Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Wu; L Barbara-Burnham; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Action of Dicumarol on Glucosamine-1-Phosphate Acetyltransferase of GlmU and Mycobacterium tuberculosis.

Authors:  Xiuyan Han; Changming Chen; Qiulong Yan; Liqiu Jia; Ayaz Taj; Yufang Ma
Journal:  Front Microbiol       Date:  2019-08-20       Impact factor: 5.640

10.  Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.

Authors:  Yu-Min Chuang; Noton K Dutta; James T Gordy; Victoria L Campodónico; Michael L Pinn; Richard B Markham; Chien-Fu Hung; Petros C Karakousis
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.